CXCL8 and kidney cancer: In advanced kidney cancer with TTM treatment in a phase II trial, stable disease was achieved in 31% of patients, and proangiogenic molecules of interleukin-6, interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in serum decreased to realise anti-angiogenic effects (Redman et al., 2003).